MaxCyte (NASDAQ:MXCT – Get Free Report) and Mettler-Toledo International (NYSE:MTD – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Institutional and Insider Ownership
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
MaxCyte has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -121.16% | -20.03% | -17.14% |
| Mettler-Toledo International | 21.91% | -1,212.14% | 25.11% |
Earnings and Valuation
This table compares MaxCyte and Mettler-Toledo International”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $32.29 million | 3.92 | -$44.63 million | ($0.37) | -3.19 |
| Mettler-Toledo International | $4.13 billion | 6.93 | $869.19 million | $44.43 | 32.17 |
Mettler-Toledo International has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and price targets for MaxCyte and Mettler-Toledo International, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
| Mettler-Toledo International | 0 | 7 | 6 | 0 | 2.46 |
MaxCyte currently has a consensus price target of $5.00, indicating a potential upside of 323.73%. Mettler-Toledo International has a consensus price target of $1,461.27, indicating a potential upside of 2.25%. Given MaxCyte’s higher possible upside, equities research analysts clearly believe MaxCyte is more favorable than Mettler-Toledo International.
Summary
Mettler-Toledo International beats MaxCyte on 10 of the 14 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Mettler-Toledo International
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company’s laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company’s retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
